Show simple item record

dc.contributor.authorSacristán, José Antonio
dc.contributor.authorLizán Tudela, Luis
dc.contributor.authorComellas, Marta
dc.contributor.authorGarrido, Pilar
dc.contributor.authorAvendaño, Cristina
dc.contributor.authorCruz-Hernández, Juan J.
dc.contributor.authorEspinosa, Javier
dc.contributor.authorDilla, Tatiana
dc.date.accessioned2017-01-25T08:22:43Z
dc.date.available2017-01-25T08:22:43Z
dc.date.issued2016
dc.identifier.citationSACRISTÁN, José A., et al. Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology. Advances in Therapy, 2016, vol. 33, no 11, p. 2059-2068ca_CA
dc.identifier.issn0741-238X
dc.identifier.issn1865-8652
dc.identifier.urihttp://hdl.handle.net/10234/165650
dc.description.abstractIntroduction The purpose of this study was to explore the main factors explaining the relative weight of the different attributes that determine the value of oncologic treatments from the different perspectives of healthcare policy makers (HCPM), oncologists, patients and the general population in Spain. Methods Structured interviews were conducted to assess: (1) the importance of the attributes on treatment choice when comparing a new cancer drug with a standard cancer treatment; (2) the importance of survival, quality of life (QoL), costs and innovation in cancer; and (3) the most worrying side effects related to cancer drugs. Results A total of 188 individuals participated in the study. For all participants, when choosing treatments, the best rated characteristics were greater efficacy, greater safety, treatment adaptation to patients’ individual requirements and the rapid reincorporation of patients to their daily activities. There were important differences among participants in their opinion about survival, QoL and cost. In general, oncologists, patients, and the general population gave greater value to gains in QoL than healthcare policy makers. Compared to other participants healthcare policy makers gave greater importance to the economic impact related to oncology treatments. Conclusions Gains in QoL, survival, safety, cost and innovation are perceived differently by different groups of stakeholders. It is recommended to consider the perspective of different stakeholders in the assessment of a new cancer drugs to obtain more informed decisions when deciding on the most appropriate treatment to useca_CA
dc.description.sponsorShipThe authors are extremely grateful to all study participants who contributed with their time to participate in this research. Sponsorship, publication charges, and the open access charge for this study were funded by Eli Lilly & Co, Madrid (Spain). All named authors meet the International Committee of Medical Journal Editors criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.ca_CA
dc.format.extent10 p.ca_CA
dc.format.mimetypeapplication/pdfca_CA
dc.language.isoengca_CA
dc.publisherSpringerca_CA
dc.relation.isPartOfAdvances in Therapy, 2016, vol. 33, no 11ca_CA
dc.rightsThe Author(s) 2016ca_CA
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectclinically meaningful outcomesca_CA
dc.subjectinnovationca_CA
dc.subjectoncologyca_CA
dc.subjectSpainca_CA
dc.subjectvalueca_CA
dc.titlePerceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncologyca_CA
dc.typeinfo:eu-repo/semantics/articleca_CA
dc.identifier.doihttp://dx.doi.org/10.1007/s12325-016-0415-5
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_CA
dc.relation.publisherVersionhttp://link.springer.com/article/10.1007%2Fs12325-016-0415-5ca_CA


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

The Author(s) 2016
Except where otherwise noted, this item's license is described as The Author(s) 2016